The COVID-19 pandemic has shone a spotlight on the need for timely access to vaccines. This is the case not only for safe and effective COVID-19 vaccines – for which we have benefitted from unparalleled speed when it comes to access and rollout – but also for other routine and novel vaccines.
Across Europe, the time taken for a vaccine between the marketing authorization to the moment it reaches the population is highly variable. Some countries ensure access in 2 years, but for others, it can take more than 6 years.
Addressing these differences is essential for improving vaccine market access in the EU.
Help us to share the word! Download the communication toolkit here (EMBARGO until 2PM on March 22nd)